AU2013224041B2 - Thiadiazolidinediones as GSK-3 inhibitors - Google Patents

Thiadiazolidinediones as GSK-3 inhibitors Download PDF

Info

Publication number
AU2013224041B2
AU2013224041B2 AU2013224041A AU2013224041A AU2013224041B2 AU 2013224041 B2 AU2013224041 B2 AU 2013224041B2 AU 2013224041 A AU2013224041 A AU 2013224041A AU 2013224041 A AU2013224041 A AU 2013224041A AU 2013224041 B2 AU2013224041 B2 AU 2013224041B2
Authority
AU
Australia
Prior art keywords
compound
formula
inhibitors
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013224041A
Other languages
English (en)
Other versions
AU2013224041A1 (en
Inventor
Javier DE CRISTOBAL BLANCO
Juan Manuel Dominguez Correa
Ana Fuertes Huerta
Susana Herrero Santos
Javier Lopez Ogalla
Olga Martinez Montero
Miguel Medina Padilla
Francisco Palomo Nicolau
Maria Angeles Perez De La Cruz Moreno
Beatriz Rodriguez Salguero
Jorge Sanchez-Quesada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASD Therapeutics Partners LLC
Original Assignee
ASD Therapeutics Partners LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASD Therapeutics Partners LLC filed Critical ASD Therapeutics Partners LLC
Publication of AU2013224041A1 publication Critical patent/AU2013224041A1/en
Application granted granted Critical
Publication of AU2013224041B2 publication Critical patent/AU2013224041B2/en
Priority to AU2017248556A priority Critical patent/AU2017248556B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013224041A 2012-02-24 2013-02-22 Thiadiazolidinediones as GSK-3 inhibitors Active AU2013224041B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017248556A AU2017248556B2 (en) 2012-02-24 2017-10-20 Thiadiazolidinediones as gsk-3 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382066 2012-02-24
EP12382066.4 2012-02-24
PCT/EP2013/053554 WO2013124413A1 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as gsk-3 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017248556A Division AU2017248556B2 (en) 2012-02-24 2017-10-20 Thiadiazolidinediones as gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
AU2013224041A1 AU2013224041A1 (en) 2014-09-25
AU2013224041B2 true AU2013224041B2 (en) 2017-08-24

Family

ID=47747639

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013224041A Active AU2013224041B2 (en) 2012-02-24 2013-02-22 Thiadiazolidinediones as GSK-3 inhibitors
AU2017248556A Active AU2017248556B2 (en) 2012-02-24 2017-10-20 Thiadiazolidinediones as gsk-3 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017248556A Active AU2017248556B2 (en) 2012-02-24 2017-10-20 Thiadiazolidinediones as gsk-3 inhibitors

Country Status (18)

Country Link
US (2) US9371299B2 (enExample)
EP (1) EP2838888B1 (enExample)
JP (2) JP6073377B2 (enExample)
AU (2) AU2013224041B2 (enExample)
CA (1) CA2865351C (enExample)
CY (1) CY1119231T1 (enExample)
DK (1) DK2838888T3 (enExample)
ES (1) ES2632428T3 (enExample)
HR (1) HRP20170964T1 (enExample)
HU (1) HUE035089T2 (enExample)
IN (1) IN2014DN07885A (enExample)
LT (1) LT2838888T (enExample)
NZ (1) NZ630615A (enExample)
PL (1) PL2838888T3 (enExample)
PT (1) PT2838888T (enExample)
SI (1) SI2838888T1 (enExample)
WO (1) WO2013124413A1 (enExample)
ZA (1) ZA201406225B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371299B2 (en) 2012-02-24 2016-06-21 Asd Therapeutics Partners, Llc Thiadiazolidinediones as GSK-3 inhibitors
WO2014159356A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
JP6663863B2 (ja) * 2014-06-12 2020-03-13 シーダーズ−サイナイ メディカル センター がん治療のための組成物及び方法
IL299964A (en) 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020079576A1 (en) * 2018-10-16 2020-04-23 Italia Technology Alliance S.R.L. Winding machine with an evaluation system of the web material being processed and method
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
AU2022219157A1 (en) * 2021-02-11 2023-08-10 Venca Research, Inc. Compositions and methods for treating arrhythmogenic cardiomyopathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033012A1 (en) * 2000-05-11 2008-02-07 Cosenjo Superior De Investigaciones Cientificas, A Spain Corporation Enzyme inhibitors
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
US9371299B2 (en) 2012-02-24 2016-06-21 Asd Therapeutics Partners, Llc Thiadiazolidinediones as GSK-3 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033012A1 (en) * 2000-05-11 2008-02-07 Cosenjo Superior De Investigaciones Cientificas, A Spain Corporation Enzyme inhibitors
KR100837785B1 (ko) * 2007-01-17 2008-06-13 한국화학연구원 1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number 1350207-15-6; STN Entry Date 7 December 2011; 4-methyl-2-(phenylmethyl)-1,2,4-Thiadiazolidine-3,5-dione *

Also Published As

Publication number Publication date
JP6073377B2 (ja) 2017-02-01
ES2632428T3 (es) 2017-09-13
EP2838888B1 (en) 2017-04-12
HUE035089T2 (hu) 2018-05-02
LT2838888T (lt) 2017-08-10
HRP20170964T1 (hr) 2017-10-06
AU2017248556B2 (en) 2018-08-09
AU2017248556A1 (en) 2017-11-09
WO2013124413A1 (en) 2013-08-29
PL2838888T3 (pl) 2017-12-29
US9469618B2 (en) 2016-10-18
CA2865351A1 (en) 2013-08-29
CY1119231T1 (el) 2018-02-14
DK2838888T3 (en) 2017-07-17
PT2838888T (pt) 2017-07-18
JP2015508092A (ja) 2015-03-16
AU2013224041A1 (en) 2014-09-25
HK1207366A1 (en) 2016-01-29
SI2838888T1 (sl) 2017-09-29
US20160257660A1 (en) 2016-09-08
JP6518270B2 (ja) 2019-05-22
ZA201406225B (en) 2016-05-25
NZ630615A (en) 2015-09-25
EP2838888A1 (en) 2015-02-25
JP2017081974A (ja) 2017-05-18
US9371299B2 (en) 2016-06-21
IN2014DN07885A (enExample) 2015-04-24
US20150038538A1 (en) 2015-02-05
CA2865351C (en) 2019-08-20

Similar Documents

Publication Publication Date Title
AU2017248556B2 (en) Thiadiazolidinediones as gsk-3 inhibitors
TWI352084B (en) Gsk-3 inhibitors
KR101471999B1 (ko) Ｇｓｋ-3 저해제
AU2007245625B2 (en) N- ( 2-thiazolyl) -amide derivatives as GSK-3 inhibitors
EP3134410B1 (en) Inhibiting the transient receptor potential a1 ion channel
AU2015229188A1 (en) Compounds, compositions, and methods for increasing CFTR activity
EP1406883B1 (en) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3)
JP2004505983A (ja) ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法
HK1207366B (en) Thiadiazolidinediones as gsk-3 inhibitors
WO2013149976A1 (en) Indole-pyrimidine derivatives and their therapeutic uses
EP2527322A1 (en) Carbamyl alkylphenyl disulfide derivatives and their therapeutic uses
EP2527323A1 (en) Urea carbonyl disulfide derivatives and their therapeutic uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)